Stem Cell Stocks Seek Comeback
Dont expect stem cell stocks to lag the rest of the biotech sector again in 2014, says Dr. Robin Smith, CEO of Neostem.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
